The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
Research Funding - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER
Other Relationship - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst)
 
Consulting or Advisory Role - Amgen; Bayer; Sanofi
Speakers' Bureau - Amgen; Bayer; Roche; Sanofi
Research Funding - Amgen (Inst); Bayer (Inst); Merck Serono (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; CheckmAb; Clovis Oncology; Daiichi Sankyo; Incyte; Merck; Novartis; Roche/Genentech; Seagen
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Maria Di Bartolomeo
Honoraria - Lilly; MSD Oncology; SERVIER
Consulting or Advisory Role - Lilly; MSD Oncology
Research Funding - Lilly
Travel, Accommodations, Expenses - Roche; Sanofi
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Eisai
 
Toshiki Masuishi
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck Serono; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Yakult Honsha
 
Fotios Loupakis
No Relationships to Disclose
 
Hisato Kawakami
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst)
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Tomohiro Nishina
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Nihonkayaku; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Marwan Fakih
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche
Speakers' Bureau - Amgen; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Elena Elez
No Relationships to Disclose
 
Javier Rodriguez
No Relationships to Disclose
 
Fortunato Ciardiello
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst)
 
Kapil Saxena
Employment - Daiichi Sankyo
 
Eriko Yamamoto
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Emarjola Bako
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Yasuyuki Okuda
Employment - Daiichi Sankyo
 
Javad Shahidi
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Axel Grothey
Honoraria - Aptitude Health; Elsevier; IMEDEX
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst)
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bayer; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)